Found: 44
Select item for more details and to access through your institution.
Outcomes of immunotherapy-related hepatotoxicity from a multi-disciplinary toxicity team.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 2, p. 877, doi. 10.1007/s00432-022-04299-1
- By:
- Publication type:
- Article
Checkpoint Inhibitor Pneumonitis: Mechanisms, Characteristics, Management Strategies, and Beyond.
- Published in:
- Current Oncology Reports, 2020, v. 22, n. 6, p. 1, doi. 10.1007/s11912-020-00920-z
- By:
- Publication type:
- Article
Correction to: The gut microbiome, immune check point inhibition and immune‑related adverse events in non‑small cell lung cancer.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer.
- Published in:
- Cancer & Metastasis Reviews, 2022, v. 41, n. 2, p. 347, doi. 10.1007/s10555-022-10039-1
- By:
- Publication type:
- Article
Lung cancer and family-centered concerns.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Editorial: Optimizing outcomes and addressing adversities of immunotherapy in lung cancer.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1277542
- By:
- Publication type:
- Article
Immune-related adverse events and the balancing act of immunotherapy.
- Published in:
- Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-27960-2
- By:
- Publication type:
- Article
Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non-Small-Cell Lung Cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Lower Survival in Patients Who Develop Pneumonitis Following Immunotherapy for Lung Cancer.
- Published in:
- 2020
- By:
- Publication type:
- Letter
Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung Cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Immunotherapy for Stage III NSCLC: Durvalumab and Beyond.
- Published in:
- Lung Cancer: Targets & Therapy, 2021, v. 12, p. 123, doi. 10.2147/LCTT.S305466
- By:
- Publication type:
- Article
Cardiovascular complications of immune checkpoint inhibitors for cancer.
- Published in:
- European Heart Journal, 2022, v. 43, n. 42, p. 4458, doi. 10.1093/eurheartj/ehac456
- By:
- Publication type:
- Article
Mutation status and postresection survival of patients with non-small cell lung cancer brain metastasis: implications of biomarker-driven therapy.
- Published in:
- Journal of Neurosurgery, 2022, v. 136, n. 1, p. 56, doi. 10.3171/2020.10.JNS201787
- By:
- Publication type:
- Article
Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Pneumonitis From Anti--PD-1/ PD-L1 Therapy.
- Published in:
- Oncology (08909091), 2017, v. 31, n. 10, p. 739
- By:
- Publication type:
- Article
Optimizing the Delivery of Antineoplastic Therapies to the Central Nervous System.
- Published in:
- Oncology (08909091), 2016, v. 30, n. 11, p. 953
- By:
- Publication type:
- Article
Murine fecal microbiota transfer models selectively colonize human microbes and reveal transcriptional programs associated with response to neoadjuvant checkpoint inhibitors.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 10, p. 2405, doi. 10.1007/s00262-022-03169-6
- By:
- Publication type:
- Article
4401 Incidence, management, and outcomes of immune-related adverse events (irAEs): an analysis of a multidisciplinary toxicity team for cancer immunotherapy related irAEs.
- Published in:
- 2020
- By:
- Publication type:
- Abstract
Early-Stage Non-Small Cell Lung Cancer: New Challenges with Immune Checkpoint Blockers and Targeted Therapies.
- Published in:
- Cancers, 2024, v. 16, n. 16, p. 2779, doi. 10.3390/cancers16162779
- By:
- Publication type:
- Article
Is Immunotherapy Beneficial in Patients with Oncogene-Addicted Non-Small Cell Lung Cancers? A Narrative Review.
- Published in:
- Cancers, 2024, v. 16, n. 3, p. 527, doi. 10.3390/cancers16030527
- By:
- Publication type:
- Article
Immunotherapy through the Lens of Non-Small Cell Lung Cancer.
- Published in:
- Cancers, 2023, v. 15, n. 11, p. 2996, doi. 10.3390/cancers15112996
- By:
- Publication type:
- Article
Cardiovascular toxicities associated with immune checkpoint inhibitors.
- Published in:
- Cardiovascular Research, 2019, v. 115, n. 5, p. 854, doi. 10.1093/cvr/cvz026
- By:
- Publication type:
- Article
Correction to: The cost of cancer care: how far would you go for a trial?
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
The cost of cancer care: how far would you go for a trial?
- Published in:
- Irish Journal of Medical Science, 2022, v. 191, n. 6, p. 2487, doi. 10.1007/s11845-021-02915-6
- By:
- Publication type:
- Article
Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer.
- Published in:
- Therapeutic Advances in Medical Oncology, 2018, v. 10, n. 1, p. 1, doi. 10.1177/1758835918778297
- By:
- Publication type:
- Article
Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer.
- Published in:
- 2018
- By:
- Publication type:
- journal article
The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis.
- Published in:
- 2019
- By:
- Publication type:
- journal article
An adapted anti-CTLA4 therapeutic aimed at mitigating the toxicities of checkpoint inhibition.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Toxicity of immune checkpoint inhibitors and tyrosine kinase inhibitor combinations in solid tumours: a systematic review and meta-analysis.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1380453
- By:
- Publication type:
- Article
Immune-Related Adverse Events: A Case-Based Approach.
- Published in:
- Frontiers in Oncology, 2019, p. N.PAG, doi. 10.3389/fonc.2019.00530
- By:
- Publication type:
- Article
Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers.
- Published in:
- PLoS ONE, 2016, v. 11, n. 1, p. 1, doi. 10.1371/journal.pone.0146063
- By:
- Publication type:
- Article
The Next Frontier in Non-Small Cell Lung Cancer: Synergizing Radiation Therapy and Immune Checkpoint Blockade.
- Published in:
- Clinical Advances in Hematology & Oncology, 2017, v. 15, n. 8, p. 615
- By:
- Publication type:
- Article
Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib.
- Published in:
- Cancer (0008543X), 2015, v. 121, n. 18, p. 3212, doi. 10.1002/cncr.29493
- By:
- Publication type:
- Article
Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.
- Published in:
- Cancer (0008543X), 2015, v. 121, n. 12, p. 2078, doi. 10.1002/cncr.29313
- By:
- Publication type:
- Article
Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy.
- Published in:
- Oncologist, 2022, v. 27, n. 11, p. 971, doi. 10.1093/oncolo/oyac140
- By:
- Publication type:
- Article
Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies.
- Published in:
- Oncologist, 2021, v. 26, n. 10, p. e1822, doi. 10.1002/onco.13900
- By:
- Publication type:
- Article
A Multidisciplinary Approach for Patients with Preexisting Lung Diseases and Immune Checkpoint Inhibitor Toxicities.
- Published in:
- Oncologist, 2020, v. 25, n. 11, p. e1589, doi. 10.1634/theoncologist.2020-0266
- By:
- Publication type:
- Article
Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade.
- Published in:
- Oncologist, 2017, v. 22, n. 6, p. 627, doi. 10.1634/theoncologist.2016-0390
- By:
- Publication type:
- Article
Sex-specific differences in immunogenomic features of response to immune checkpoint blockade.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.945798
- By:
- Publication type:
- Article
Information Visualization Platform for Postmarket Surveillance Decision Support.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors.
- Published in:
- PLoS ONE, 2017, v. 12, n. 8, p. 1, doi. 10.1371/journal.pone.0182665
- By:
- Publication type:
- Article
Prospective Clinical Trials to Advance the Study of Immune Checkpoint Inhibitor Toxicity.
- Published in:
- Current Oncology, 2023, v. 30, n. 7, p. 6862, doi. 10.3390/curroncol30070502
- By:
- Publication type:
- Article
An Oncology Urgent Care Clinic for the Management of Immune-Related Adverse Events: A Descriptive Analysis.
- Published in:
- Current Oncology, 2022, v. 29, n. 6, p. 4342, doi. 10.3390/curroncol29060347
- By:
- Publication type:
- Article